MDM4 and idiopathic pulmonary fibrosis: Among them, nintedanib17,18, an FDA-approved multikinase inhibitor for Idiopathic Pulmonary Fibrosis (IPF), showcased the potential as a new MDM2/MDMX dual inhibitor, and this was validated by a series of structural and biochemical analyses.